Zenith Epigenetics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 4820 Richard Rd SW, Calgary, Alberta...Phone Number
(587) 390-7865Website
www.zenithepigenetics.comRevenue
<$5 MillionStock Symbol
ZHCLFIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Zenith Epigenetics
Zenith Epigenetics is a clinical-stage biotechnology company focused on developing advanced bromodomain and extra-terminal inhibitors (BETi) for treating various cancers and disorders with significant unmet medical needs. The company aims to lead in oncology by translating bromodomain biology into effective, targeted therapeutics. Collaborating with top oncology institutions, Zenith is creating combination therapies to enhance treatment efficacy and patient outcomes. Their lead candidate, ZEN-3694, is currently in clinical trials for multiple cancer types, demonstrating promising results in overcoming drug resistance.Explore more
Zenith Epigenetics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zenith Epigenetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Zenith Epigenetics is spiking on competitors!
Zenith Epigenetics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Zenith Epigenetics had a recent Job posting/layoffs
Earning: See what the market has to say on Zenith Epigenetics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Zenith Epigenetics
Funding: Get notified immidiatlly once Zenith Epigenetics has new funding data
Product Launch: Get notified when Zenith Epigenetics launches new products
Check if Zenith Epigenetics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Zenith Epigenetics as Masked Content
Find more new buyers
Compare Similar Companies to Zenith Epigenetics
Compare insights from companies similar to Zenith Epigenetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zenith Epigenetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zenith Epigenetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zenith Epigenetics.
Zenith Epigenetics financials insights
Gather financial insights about Zenith Epigenetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$8M
Private Equity
$4.3M
Zenith Epigenetics Tech Stack
A closer look at the technologies used by Zenith Epigenetics
See more technologies
Zenith Epigenetics News & Media
Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC). NC is a highly aggressive type of squamous cell cancer with very poor prognosis that often forms in the head, neck, or lungs. There are currently no effective treatments for this devastating disease that primarily affects adolescents and young adultsZenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or chemotherapy in several solid tumor types with significant unmet need Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or chemotherapy in several solid tumor types with significant unmet needZenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
Zenith’s ASCO Poster was Also Awarded the GRASP Advocate Choice Award by a Patient Advocacy GroupCALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna (talazoparib) was highlighted at an oral session “Optimizing Targeted Therapies in Advanced Breast Cancer: Building on Past Success”. The discusZenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
Data from the completed Phase 1b/2 trial to be presented at the American Society of Clinical Oncology (ASCO) Conference in an oral poster discussion session Data from the completed Phase 1b/2 trial to be presented at the American Society of Clinical Oncology (ASCO) Conference in an oral poster discussion session
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zenith Epigenetics
Sign Up For FreeTo access detailed company insights
Zenith Epigenetics is a clinical-stage biotechnology company focused on developing advanced bromodomain and extra-terminal inhibitors (BETi) for treating various cancers and disorders with significant unmet medical needs. The company aims to lead in oncology by translating bromodomain biology into effective, targeted therapeutics. Collaborating wit... Read More
